Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immatics N.V. stock logo
IMTX
Immatics
$7.59
-10.1%		$9.04
$7.40
▼
$12.41
$1.15B1.36703,809 shs1.26 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$13.07
-2.8%		$13.26
$1.50
▼
$16.33
$1.26B0.932.10 million shs1.30 million shs
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$5.67
$5.64
$2.20
▼
$6.28
$302.20M0.31953,834 shsN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.69
+3.5%		$22.09
$6.50
▼
$39.49
$1.07B1.781.31 million shs773,269 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immatics N.V. stock logo
IMTX
Immatics
-10.07%-9.32%-20.11%-23.72%-15.67%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-2.83%+5.74%-18.21%+12.87%+210.45%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
0.00%0.00%0.00%0.00%+0.18%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+3.49%+0.92%-24.52%-9.23%-52.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immatics N.V. stock logo
IMTX
Immatics
$7.59
-10.1%		$9.04
$7.40
▼
$12.41
$1.15B1.36703,809 shs1.26 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$13.07
-2.8%		$13.26
$1.50
▼
$16.33
$1.26B0.932.10 million shs1.30 million shs
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$5.67
$5.64
$2.20
▼
$6.28
$302.20M0.31953,834 shsN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.69
+3.5%		$22.09
$6.50
▼
$39.49
$1.07B1.781.31 million shs773,269 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immatics N.V. stock logo
IMTX
Immatics
-10.07%-9.32%-20.11%-23.72%-15.67%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-2.83%+5.74%-18.21%+12.87%+210.45%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
0.00%0.00%0.00%0.00%+0.18%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+3.49%+0.92%-24.52%-9.23%-52.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immatics N.V. stock logo
IMTX
Immatics
2.63
Moderate Buy$20.60171.41% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
2.60
Moderate Buy$12.00-8.19% Downside
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
1.00
SellN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90
Moderate Buy$41.71123.19% Upside

Current Analyst Ratings Breakdown

Latest SCPH, REPL, IMTX, and VOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Immatics N.V. stock logo
IMTX
Immatics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/14/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/26/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$20.00 ➝ $21.00
8/25/2026
Immatics N.V. stock logo
IMTX
Immatics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$17.00
8/12/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/12/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$18.00 ➝ $27.00
8/11/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/7/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Outperform$12.00
8/7/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$17.00 ➝ $20.00
8/4/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immatics N.V. stock logo
IMTX
Immatics
$41.70M24.88N/AN/A$4.09 per share1.86
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$2.01 per shareN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$49.97M6.05N/AN/A$0.27 per share21.00
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immatics N.V. stock logo
IMTX
Immatics
-$222.26M-$1.86N/AN/AN/A-495.71%-47.41%-39.45%11/17/2026 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$313.94M-$3.15N/AN/AN/AN/A-159.32%-90.84%11/5/2026 (Estimated)
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%N/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest SCPH, REPL, IMTX, and VOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q2 2026
Immatics N.V. stock logo
IMTX
Immatics
-$0.4748-$0.53-$0.0552-$0.52$12.42 million$10.44 million
8/14/2026Q1 2027
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.6940-$0.72-$0.0260-$0.72$13.60 millionN/A
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Immatics N.V. stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immatics N.V. stock logo
IMTX
Immatics
N/A
7.54
7.54
Replimune Group, Inc. stock logo
REPL
Replimune Group
1.00
5.23
5.23
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/A
3.85
3.14
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Immatics N.V. stock logo
IMTX
Immatics
64.41%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Immatics N.V. stock logo
IMTX
Immatics
3.30%
Replimune Group, Inc. stock logo
REPL
Replimune Group
5.40%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.78%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immatics N.V. stock logo
IMTX
Immatics
704136.69 million132.18 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
46593.80 million88.73 millionOptionable
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3053.30 million50.75 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
7659.16 million59.00 millionN/A

Recent News About These Companies

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened
September 30 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-jumps-53-heres-what-happened-2026-09-30/
Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69706309-vor-biopharma-telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis-399.htm
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29, 2026  |  marketscreener.comM
Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes
September 29, 2026  |  boursorama.comB
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370807/0/en/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis.html
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
September 29, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VOR/pressreleases/4850802/vor-biopharma-vor-gets-a-buy-from-stifel-nicolaus/
Vor Biopharma Inc. (NASDAQ:VOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056562
Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-stock-has-average-price-target-of-4171-according-to-brokerages-2026-09-28/
【VOR】Vor Biopharma
September 23, 2026  |  note.comN
Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia
September 23, 2026  |  br.investing.comhttps://br.investing.com/news/transcripts/vor-biopharma-no-forum-stifel-2026-telitacicept-aposta-em-dupla-estrategia-93CH-2073344
Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局
September 23, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3580464
Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia
September 23, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/vor-biopharma-al-forum-stifel-2026-telitacicept-punta-su-doppia-strategia-93CH-3560029
Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía
September 23, 2026  |  mx.investing.comhttps://mx.investing.com/news/transcripts/vor-biopharma-en-foro-stifel-2026-telitacicept-avanza-en-doble-via-93CH-3774116
Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-shares-down-82-should-you-sell-2026-09-23/
Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-trading-up-61-still-a-buy-2026-09-22/
Vor Biopharma: A Funded Replication Story With Franchise Potential
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947759-vor-biopharma-a-funded-replication-story-with-franchise-potential
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VOR/latest-news/
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944756-vor-biopharma-inc-vor-presents-at-citigroups-biopharma-back-to-school-summit-2026-transcript
Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-down-54-should-you-sell-2026-09-09/
97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-97722-shares-in-vor-biopharma-inc-vor-purchased-by-bank-of-new-york-mellon-corp-2026-09-09/
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
September 8, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immatics stock logo

Immatics NASDAQ:IMTX

$7.59 -0.85 (-10.07%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$7.59 0.00 (0.00%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$13.07 -0.38 (-2.83%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$13.14 +0.07 (+0.57%)
As of 10/2/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$18.69 +0.63 (+3.49%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$18.77 +0.08 (+0.45%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas